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Cancer cells exhibit metabolic alterations that distinguish them from healthy tissues and make their metabolic processes
susceptible to pharmacological targeting. Although typical cell-autonomous features of cancer metabolism have been emerging,
it is increasingly appreciated that extrinsic factors also influence the metabolic properties of tumours. This review highlights
evidence from the recent literature to discuss how conditions within the tumour microenvironment shape the metabolic character
of tumours.
A primary goal in designing new cancer therapies is to target
cancer cells specifically and, at the same time, spare healthy tissues.
Cancer cells exhibit, among others, characteristic features in the
way they utilise nutrients to survive and proliferate. Although in
many cases the ensemble of small molecules and enzymatic
activities underlying metabolic processes in cancer are, by and
large, similar to the ones in healthy tissues, changes in the
expression levels of metabolic enzymes, expression of alternative
enzyme isoforms or mutations in genes encoding metabolic
enzymes have all been implicated in altering the metabolism of
tumours (Pavlova and Thompson, 2016). Oncogenic and tumour
suppressor pathways that drive cancer development have been
shown to promote these metabolic features, which are therefore
stably propagated throughout tumour development. This has
raised hopes that metabolic enzymes comprise good targets for
cancer therapy (Galluzzi et al, 2013; Elia et al, 2016).
Metabolism encompasses the chemical processes that allow cells
to use available nutrient resources and sustain their survival and
propagation. As such, the environment in which tumours emerge
is bound to have an influence in their metabolism: what nutrients
and other factors that enable metabolism, such as oxygen, are
available, at what quantities, whether other cells are present that
compete for or provide such nutrients are all factors that can
influence the metabolic behaviour of tumours.
This review focuses on recent advances in our understanding of
cancer metabolism with emphasis on the influence of the tumour
microenvironment. In particular, I will discuss work in mice and
humans that points to a synergism between the tumour
environment and genetics in determining the metabolic profiles
of cancers, and will put this evidence in context of the prevailing
views on how glucose and glutamine support cancer metabolism. I
will then explore factors that are thought to operate within the
tumour environment, in particular fluctuations in oxygen and
nutrient availability, and will describe newly discovered mechan-
isms by which these factors impact metabolism. Finally, I will use
select examples to outline how various tumour stromal cells, which
are also subject to similar metabolic requirements as cancer cells,
contribute to the metabolic conditions found within the tumour
microenvironment.
OVERVIEW OF CENTRAL METABOLISM—GLUCOSE AND
GLUTAMINE
Glucose is an abundant source of carbon in mammals, and organs
such as the brain and the heart exhibit high levels of glucose
uptake. Some tumours show increased glucose uptake relative to
the surrounding normal tissues and this feature has been exploited
for diagnostic imaging using 18F-deoxyglucose (FDG), a radio-
active glucose analogue that cannot be fully metabolised, for
positron emission tomography (PET).
Glucose uptake can be promoted by gene expression or
signalling changes that lead to increased glucose transporter
expression, particularly GLUT1, at the plasma membrane. Once
into cells, a major route for glucose catabolism is glycolysis
(Figure 1). Pathways that branch out of glycolysis can utilise
products of glucose catabolism for the synthesis of nucleotides,
lipids or amino acids. Depending on cell type and environmental
conditions, glucose-derived pyruvate enters into the mitochondrial
TCA cycle as an intact 3-carbon unit via pyruvate carboxylase, or
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loses one carbon as CO2 and is converted to acetyl-coA by
pyruvate dehydrogenase (PDH). Carbon metabolism in the TCA
cycle can further provide metabolic intermediates for biosynthesis
of lipids and amino acids, which, in addition to protein, are also
precursors for nucleotides and glutathione. Furthermore, the TCA
cycle concomitantly produces reducing power in the form of
NADH and FADH2 to generate the proton motive force across the
inner mitochondrial membrane required for ATP synthesis
(DeBerardinis and Chandel, 2016).
A prevailing picture is that, in tumours, a higher fraction of
glucose carbons is diverted away from mitochondria and
converted to lactate by lactate dehydrogenase (LDH), a phenom-
enon referred to as the Warburg effect. Decreased catabolism of
glucose in mitochondria had initially been attributed to
mitochondrial dysfunction, raising the apparent paradox of how
cancer cells can cope with a metabolic state that yields less energy
per glucose molecule. However, there is little evidence that ATP is
limiting for the growth of cancer cells (Israelsen and Vander
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Figure 1. Overview of pathways implicated in cancer metabolism. Key enzymes are shown in white boxes. See text for details. Coloured
block arrows denote contribution of metabolites to the respective cellular processes. DCm denotes mitochondrial inner membrane potential.
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Heiden, 2010) and, with the exception of tumours that harbour
mutations in mitochondrial metabolic enzymes (such as succinate
dehydrogenase, fumarate hydratase or isocitrate dehydrogenase),
mitochondrial function is not only intact but also required for
the growth of some tumours studied to date (Zong et al, 2016).
The significance of the Warburg effect is not entirely understood,
but is likely to be multi-dimensional. Computational modelling
suggests that it may reflect a metabolic mode that combines
efficiency for biomass and energy production, while affording
cancer cells the necessary flexibility that allows them to
adapt against various stresses (Shlomi et al, 2011; Keibler et al,
2016). Regardless, decreased entry of glucose carbons into the
TCA cycle, in combination with the efflux of its intermediates
into biosynthetic processes, imposes a need for topping up
(‘anaplerosis’) the TCA cycle by carbon sources other than
glucose.
Various nutrients have been implicated in TCA cycle anaplero-
sis. Among several amino acids that can be catabolised thought
the TCA cycle, glutamine has long been considered the
major anaplerotic source primarily due to its high abundance
in the mammalian blood relative to other amino acids. Consistent
with this, tumours that are not FDG-PET avid, may take up
more glutamine as a complementary nutrient source (Lieberman
et al, 2011)
During cell division, doubling of cellular mass imposes a need
for carbon and nitrogen required to synthesise new biomolecules
(Lunt and Vander Heiden, 2011). Together, increased glucose and
glutamine consumption by tumours have been proposed to provide
carbon and nitrogen precursors to sustain the biosynthesis of
building blocks required for proliferation. However, a recurring
observation in cultured cells is that a significant fraction of
glucose or glutamine carbons is excreted as lactate (DeBerardinis
et al, 2007; Hosios et al, 2016), which is not conducive to carbon
preservation. Furthermore, a systematic tracing of glucose and
glutamine carbons into biomass revealed that each contribute
o10% to total cell mass carbons in proliferating cultured cells
(Hosios et al, 2016; Keibler et al, 2016). These observations
suggest that the functions of glucose and glutamine catabolism
may extend beyond a role as providers of atoms for other
metabolites.
In addition to carbons and nitrogens, biosynthetic processes
require energy and reducing power provided by ATP and pyridine
nucleotides, respectively. In the process of being catabolised,
glucose and glutamine transfer electrons to nicotinamide adenine
dinucleotide (NADþ ) and its cognate phosphorylated form
NADPþ , to produce NADH and NADPH, respectively. For the
synthesis of a simple lipid molecule, more glucose needs to be
consumed to provide enough NADPH compared with the amount
of glucose that provides the required carbons or ATP (Vander
Heiden et al, 2009). Isotopic labelling studies support the notion
that a significant fraction of cellular NADPH that contributes to
lipid synthesis can be provided by glucose and glutamine
(DeBerardinis et al, 2007; Fan et al, 2014; Lewis et al, 2014).
Furthermore, despite the intimate link between the glucose and
glutamine-fuelled TCA cycle and mitochondrial membrane
potential in the context of ATP production, the cellular functions
of these processes can be distinguished. Whereas TCA cycle
activity sustains histone acetylation by incompletely under-
stood mechanisms, mitochondrial membrane potential indepen-
dently allows generation of reactive oxygen species (ROS) that, at
low levels, can promote proliferation (Martinez-Reyes et al,
2016). This adds to an increasing body of work pointing to
important roles for both glucose and glutamine in the
maintenance of cellular redox balance and in providing
precursors for epigenetic modifications, in addition to their
contribution in sustaining the supply of metabolic intermediates
for biosynthetic reactions.
THE TUMOUR MICROENVIRONMENT INFLUENCES
CANCER CELL METABOLISM
Cellular metabolites have vastly diverse physicochemical proper-
ties, thereby necessitating the combination of various analytical
methods for their detection and quantification. In some cases, the
presence of a specific metabolite may inform of the metabolic state
of a tumour; however, it is not always straightforward to infer the
activity of specific metabolic pathways from the measurement of
metabolite abundances alone (Buescher et al, 2015). The use of
stable isotope tracers has been pivotal in analysing how specific
metabolites are catabolised through various pathways by following
the distribution of the labelled element in other molecules.
Administration of 13C-labelled glucose in human lung cancer
patients identified increased contribution of glucose carbons to
the TCA cycle, as well as lactate compared with non-cancerous
extra-tumoral tissue (Sellers et al, 2015; Hensley et al, 2016).
Interestingly, both pyruvate carboxylase (PC) and PDH can
catalyse the entry of pyruvate into the TCA cycle, but the relative
contribution of PDH exceeds that of PC (Hensley et al, 2016).
Similarly, PDH was found to be essential for the growth of
autochthonous lung tumours driven by oncogenic Ras in mice
(Davidson et al, 2016). High-glucose catabolism in mitochondria
through PC has also been observed in human glioblastoma
tumours of diverse genetic backgrounds (Marin-Valencia et al,
2012). In all these cases, glutamine catabolism contributed little to
the TCA cycle and cells from the respective tumours were resilient
to glutamine withdrawal or inhibition of glutaminolysis. These
data also resonate with observations of increased flux through PC
in tumours that harbour TCA cycle enzyme mutations (Cardaci
et al, 2015), or following genetic ablation of glutamine-dependent
anaplerosis (Cheng et al, 2011). The reciprocal relationship
between PC and glutamine catabolism through the TCA cycle
reflects the importance of anaplerosis for sustaining TCA cycle
functions.
In some tumour settings, decreased reliance on anaplerosis from
exogenous glutamine is associated with the ability of these tumours
to synthesise glutamine from glucose. Efflux of glucose carbons
towards glutamine synthesis would also explain the co-existence of
PC and PDH to provide both substrates required for citrate
synthase (OAA and acetyl-coA) and maintain TCA cycle activity.
Curiously, glutamine synthesis seems to operate in parallel to
increased uptake of glutamine from the surrounding milieu,
although the contribution of circulating glutamine to the latter may
differ depending on the experimental model (Marin-Valencia et al,
2012; Tardito et al, 2015). Regardless, this evidence suggests that
glutamine catabolism in pathways other than the TCA cycle
remains important for the growth of tumours that oxidise glucose
to CO2, in particular for providing nitrogens for de novo purine
biosynthesis (Tardito et al, 2015).
The balance between glutamine synthesis and production is
determined, to a certain degree, by the genetic background of the
tumour. Mouse liver tumours induced by the Met oncogene
synthesise glutamine, whereas Myc-induced liver tumours con-
sume glutamine (Yuneva et al, 2012). In contrast, Myc-induced
tumours in the mouse lung exhibit net glutamine synthesis. These
differences may reflect an influence of the tissue and cell type from
which tumours originate on whether specific metabolic gene loci
can be expressed (Hoadley et al, 2014). However, in human lung
tumours from the same patient, heterogeneity in their ability to
oxidise glucose correlates better with the perfusion status of each
tumour than its genetic background (Hensley et al, 2016). Notably,
in an orthotopic mouse mammary gland tumour model, metastases
in the lung exhibited increased reliance on PC-dependent
anaplerosis compared with the primary tumour in vivo. Estimates
of mitochondrial pyruvate concentrations based on the distribution
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of isotopic labelling patterns and metabolic modelling, hinted that
this behaviour could arise from increased intracellular pyruvate
concentrations that fall within the optimal range for PC activity
(Christen et al, 2016). In cultured cells, increased extracellular
pyruvate concentrations led to proportional increases in intracel-
lular pyruvate, supporting the notion that substrate availability at
the metastatic site is one factor through which the niche influences
the metabolic signature of a tumour. Direct evidence that the
microenvironment modulates tumour metabolism in a manner
that is epistatic over its genetic background was provided in
experiments where mouse lung cancer cells were isolated, cultured
under standard conditions and re-introduced back into animals.
These cells showed a propensity to excrete glucose-derived lactate
and relied more on glutamine anaplerosis in contrast to the
tumours they were derived from, which showed high-glucose
oxidation and low-glutamine anaplerosis of the TCA cycle in vivo.
When these cells were re-implanted into mouse lungs, they
recovered the metabolic characteristics of the original tumours
(Davidson et al, 2016).
Taken together, these observations shed fresh light into the use
of glucose and glutamine in different autochthonous models of
cancer and suggest that the metabolism of cancer cells is malleable
to factors in their environment.
METABOLIC ADAPTATION TO LIMITING OXYGEN AND
NUTRIENT CONCENTRATIONS
Remodelling of tissues during tumour development involves the
convergence of various cell types, including fibroblasts, immune
cells and endothelial cells (Junttila and de Sauvage, 2013) each with
varying metabolic requirements (Ghesquiere et al, 2014). This
combined with changes in nutrient and oxygen concentrations due
to the dynamics of vasculature as tumours increase in mass, shape
the tumour metabolic landscape in a complex manner that involves
both cell-autonomous and non cell-autonomous mechanisms.
It is not entirely clear how tumours cope with low nutrient and
oxygen concentrations between the time such deficits are sensed,
suitable cellular responses are elicited and new vasculature is
ultimately established. Early responses to acute drops in oxygen
tension are mediated by changes in mitochondrial metabolism and,
in particular, the generation of ROS (Chandel et al, 1998; Figure 2).
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Figure 2. Overview of key metabolic pathways implicated in the response of cancer cells to low oxygen conditions. See text for details. ACSS2,
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However, ROS can also react with various biomolecules, so tumour
cells employ various mechanisms to maintain ROS homoeostasis.
NADPH is central to the ability of cells to control ROS through its
use for re-generating antioxidants such as glutathione. Deuterium
tracing analyses revealed a significant contribution of glucose to
NADPH production via the pentose phosphate pathway (PPP) for
anti-oxidant functions (Fan et al, 2014). Oncogenes that activate
the phosphoinositide-3-kinase pathway lead to increased glucose
uptake and utilisation through the PPP to produce NADPH, and
support survival following an acute increase in ROS associated with
matrix detachment (Schafer et al, 2009), a cardinal feature of
transformed cells. In hypoxia, glucose utilisation through the PPP
can be promoted by direct modification of metabolic enzymes by
ROS (Anastasiou et al, 2011) or glycosylation (Yi et al, 2012). In
some settings, the anti-oxidant roles of glucose catabolism in
hypoxia involve its turnover through glycogen, a polymer normally
used to store glucose in specific healthy tissues, such as the liver
and muscle. Glycogen accumulates in various cancer cell lines and
hypoxic tumours, and inhibition of glycogen breakdown results in
p53-induced senescence due to high levels of ROS (Favaro et al,
2012). What advantages utilisation of glycogen-derived glucose vs
exogenous glucose confer is not entirely clear. One possibility is
that glycogen may provide a dedicated pool of PPP precursors that
can be mobilised, perhaps more readily or at the required
intracellular location and after only certain stimuli, while sparing
free glucose for other functions.
Concomitantly, ROS, alongside inhibition of prolyl hydroxylases
(PHDs), are essential for the long-term survival of hypoxic
tumours by stabilising the hypoxia-inducible factor (HIF) family
of transcription factors (Majmundar et al, 2010). Genes controlled
by HIF1 include PDH kinase (PDK) and LDH. Inhibition of PDH
activity through phosphorylation by PDK, and expression of LDH,
lead to decreased entry of glucose-derived carbons into the TCA
cycle and increased conversion of pyruvate into lactate
(Papandreou et al, 2006; Figure 2).
To make glucose available for anti-oxidant functions in hypoxia,
glutamine can sustain both ATP production (Fan et al, 2013) and
lipid synthesis (Metallo et al, 2012). The latter is dependent on HIF
through an incompletely understood mechanism that involves the
reductive carboxylation of glutamine. A similar pathway for
glutamine utilisation has also been observed during anchorage-
independent growth (Jiang et al, 2016), lending further credence to
a role for reductive glutamine metabolism under conditions that
are relevant within the tumour microenvironment. In this setting,
utilisation of glutamine reductively afforded cells an enhanced
ability to detoxify mitochondrial ROS through NADPH produced
by the mitochondrial IDH2 reaction. It is unclear whether this re-
configuration of glutamine metabolism also reflects an actual need
for more lipids, as the role of de novo lipogenesis in hypoxic
tumour growth and survival is likely context specific (Kamphorst
et al, 2013). Furthermore, in various physiological settings when
extracellular fatty acids are abundant, de novo lipogenesis is
suppressed, suggesting that lipid metabolism may be further
influenced by the availability of metabolic precursors also in
hypoxia (Duarte et al, 2014; Yao et al, 2016).
Hypoxic cells accumulate lipid droplets that are essential for
their survival, especially following re-oxygenation, where they have
been proposed to provide an alternative-to-glycogen source of
antioxidants, as well as help maintain ATP levels through fatty acid
oxidation (Bensaad et al, 2014; Figure 2). Although the precise
mechanism for the anti-oxidant function of lipid droplets in cancer
cells is not clear, a cytoprotective role in hypoxia has been
demonstrated in the developing Drosophila brain, where triglycer-
ides in lipid droplets serve as a depot for polyunsaturated fatty
acids, which are particularly susceptible to oxidative damage,
thereby preventing the accumulation of harmful peroxidised lipids
in cellular membranes (Bailey et al, 2015). Interestingly, overall
fatty acid synthesis in hypoxia is suppressed (Metallo et al, 2012;
Kamphorst et al, 2013; Bensaad et al, 2014); however, glucose
contributes a large fraction of the glycerol backbone of polar lipids
(Schug et al, 2015). If this were also the case for triglycerides, the
main component of the lipid droplet core, it would help explain the
increase in lipid droplet content.
On the other hand, increased uptake of exogenous free fatty
acids by plasma membrane fatty acid carriers can provide the fatty
acid moiety of lipids (Bensaad et al, 2014), and, in some
experimental models, hypoxic cells preferentially deplete lysopho-
spholipids from their media (Kamphorst et al, 2013). Furthermore,
hypoxic cells can utilise acetate as the main source of acetyl-CoA
for lipid synthesis due to the increased expression of acetyl-CoA
synthase 2 (Kamphorst et al, 2014; Schug et al, 2015). An increased
contribution of acetate to acetyl-coA and histones has also been
observed in mouse liver cancer models (Comerford et al, 2014),
orthotopically implanted human GBM tumours in mice, as well as
human patients (Mashimo et al, 2014), which could reflect an
increased presence of hypoxic regions in these tumours (Schug
et al, 2015).
Deprivation of serum nutrients and hypoxia likely coincide in
poorly vascularised tumours and can synergise in shaping the
metabolic behaviour of hypoxic cells, although the relative
sensitivity of cancer cells to these factors may be determined by
both cell extrinsic (e.g., the relative diffusion of lipids vs oxygen
through tissues) and intrinsic mechanisms (e.g., the underlying
oncogenic driver; Kamphorst et al, 2013; Li et al, 2013; Padanad
et al, 2016; Peck et al, 2016). Emerging evidence points to an
important role of the tumour stroma as a source of nutrients in the
poorly irrigated tumour.
Increased autophagy in pancreatic stellate cells provides
sufficient alanine to surrounding cancer cells to fuel TCA cycle-
dependent biosynthetic processes (Sousa et al, 2016). Similarly,
autophagy in primary cancer-associated fibroblasts (CAFs) results
in elevated levels of dipeptides (two covalently bound amino
acids; Chaudhri et al, 2013). The metabolic fate of dipeptides
in vivo remains to be elucidated, however, CAFs derived from
lung tumours that showed low glucose uptake had increased
levels of dipeptides, suggesting that CAFs may provide an
alternative source of carbon for neighbouring cancer cells.
Metabolic synergism between cells in the tumour microenviron-
ment where non-cancer cells are spared has also been observed.
GBM tumours with low glutamine-synthesising capacity are
found in the proximity of glutamine-synthesising astrocytes
(Tardito et al, 2015).
High expression of transporters can facilitate the uptake of
amino acids from the extracellular milieu and is associated with
poor prognosis in some tumours (Kaira et al, 2012; Bhutia et al,
2015). Amino acids can also be derived from intact proteins taken
up from the interstitial fluid. Cells transformed with oncogenic Ras
have increased uptake of extracellular material via a process known
as macropinocytosis (Commisso et al, 2013; Kamphorst et al,
2015). Intriguingly, although protein-derived carbons were found
disseminated in various central metabolism pathways, the cyto-
static effects of pharmacologically inhibited macropinocytosis
could be overcome by glutamine metabolites. This finding
may suggest that a primary function of macropinocytosis is to
provide glutamine because, unlike its relative enrichment in
the mammalian circulation, glutamine is not found at higher
frequency compared with other amino acids in proteins (King and
Jukes, 1969).
Whether and how biomolecules are mobilised from the
surrounding tumour cells is relevant for further understanding
and interfering with the metabolic interplay between the tumour
stroma and cancer. Cancer cells are known to excrete micro-
vesicles, such as exosomes, which contain various biomolecules,
including RNA, DNA and proteins, and mediate intercellular
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communication (D’Souza-Schorey and Clancy, 2012). Emerging
evidence suggests that metabolites may also be part of the exosomal
cargo (Zhao et al, 2016). An alternative mechanism could involve
the internalisation of entire cells, a recently described phenomenon
named entosis (Overholtzer et al, 2007). On detachment from
extracellular matrix, some cells are engulfed by their neighbours,
wherein they are degraded in lysosomes, a prime site for amino-
acid storage. The fate of the cellular degradation products is not
clear; however, they could provide a readily available source of
metabolic fuel. It is possible that amino acids are indiscriminately
used as nutrient sources and analysis of carbon sources for biomass
production points to a significant contribution of amino acids as
biosynthetic precursors for protein (Hosios et al, 2016). However,
there is ample evidence for specific, non-redundant functions of
some amino acids.
Serine is a non-essential amino acid that can be synthesised from
glucose, although some cells import it, depending on their genetic
background. Cells lacking functional p53 are more sensitive to serine
deprivation both in culture and when grown as xenografts in mice
(Maddocks et al, 2013). Serine is important for de novo synthesis of
ATP, which may have a broad influence on cellular metabolism.
Among others, serine-derived ATP provides the adenosine moiety of
S-adenosyl-methionine, a key methyl-donor for methylation reac-
tions that regulate epigenetic gene expression (Locasale, 2013;
Figure 1). Serine catabolism through the same pathway also provides
a significant source of NADPH for lipid synthesis (Fan et al, 2014).
Branched-chain amino acids have long been linked to proliferative
signaling, as activators of the mechanistic target of rapamycin
pathway. Branched-chain amino acid catabolism through branched
chain amino acid amino transferases may also provide an alternative
source of metabolic precursors to sustain glioblastoma proliferation
(Tonjes et al, 2013).
Together, the observations above highlight potential roles of the
tumour niche, and in particular fibroblasts, as a complementary
source for alternative nutrients to those provided by the
circulation. However, cancer cells may engage in further metabolic
interplay with other cell types in their vicinity in a way that
influences tumour progression.
INFLUENCE OF METABOLISM ON CELLULAR DYNAMICS
IN THE TUMOUR MICROENVIRONMENT
The role of the immune system to tumorigenesis is complex, and
although in some settings inflammation has a tumour-promoting
role, it is also clear that evading recognition by the immune system
is a cardinal feature of cancer. The metabolic needs of immune
cells implicated in tumorigenesis vary widely depending both
on their subtype and activation status (Pearce et al, 2013; O’Neill
et al, 2016).
Tryptophan is a precursor for de novo synthesis of NAD
(Figure 3A). The first step of tryptophan metabolism is catalysed
by indoleamine diooxygenase or tryptophan dioxygenase (IDO and
TDO, respectively), which produce N-formyl-kynurenine, a
precursor of kynurenine. Kynurenine is an endogenous ligand
for aryl hydrocarbon receptor (AhR), a transcription factor also
known to respond to environmental toxins. In gliomas, high TDO
expression and associated kynurenine levels lead to increased AhR
activity to promote tumorigenesis (Opitz et al, 2011). In contrast,
mouse liver cancer is promoted by suppression of tryptophan
catabolism (Tummala et al, 2014). This was attributed to the
decreased NAD production that results in suboptimal activity of
the NAD-dependent DNA repair enzyme poly-ADP ribose
polymerase.
The fact that both increased or decreased tryptophan catabolism
are associated with tumorigenesis, albeit at different tissues, is
seemingly contradictory. Intriguingly, in the same model of liver
cancer, there is increased IL-17A due to infiltrating Th17 cells,
which contributes to an inflammatory environment that promotes
steatosis, a predisposing factor to hepatocellular carcinoma (Gomes
et al, 2016). Aryl hydrocarbon receptor is essential for Th17
differentiation and tryptophan promotes Th17 differentiation in
culture (Veldhoen et al, 2008; Veldhoen et al, 2009). It is possible
that a reciprocal relationship exists between kynurenine and NAD
production, where diversion of tryptophan carbons to kynurenine
depletes precursors for NAD synthesis and vice versa. Alterna-
tively, suppressed tryptophan catabolism may be occurring early
enough in the HCC model, leading to increased available
tryptophan thereby providing a favourable niche for Th17
differentiation (Figure 3A).
In activated T cells, PEP produced through glycolysis inhibits
the sequestration of calcium in the endoplasmic reticulum (ER)
by binding to and allosterically inhibiting sarcoplasmic/ER
calcium ATPase (Figure 3B). This leads to a sustained increase
in cytoplasmic calcium to activate NFAT, a transcription factor
that mediates anti-tumour T-cell functions (Ho et al, 2015). In a
mouse model of melanoma, glucose concentrations in the
tumour interstitial fluid were 15 times lower than in the
circulation due to high glycolysis by the tumour. Concomitantly,
infiltrating tumour lymphocytes exhibited signs of glucose
deprivation and decreased NFAT activity. Upregulation of PEP
production in T cells by overexpression of PEP carboxykinase,
preserved PEP levels under glucose-poor conditions and
ameliorated tumour clearance. Intriguingly, signalling down-
stream of the PD-L1 receptor in cancer cells enhances tumour
glycolysis (Chang et al, 2015), so immunotherapies targeting
PD-L1 suppress tumour growth not only by enabling better
tumour recognition by the immune system but also by interfering
with tumour glycolysis.
The role of glucose metabolism in the stroma extends to
endothelial cells, which are key components of new blood vessels
that feed tumours. In diverse pathological settings, endothelial cell
proliferation is accompanied by increased glycolysis that can be
suppressed by inhibition of the glycolytic enzyme phosphofructo-
kinase-2/fructose-2,6-bisphosphatase 3 (De Bock et al, 2013;
Schoors et al, 2014). Phosphofructokinase-2/fructose-2,6-bispho-
sphatase 3-dependent glycolysis, and the ensuing production of
ATP, is also required for essential cytoskeletal rearrangements of
pioneer cells, known as tip cells, in newly forming vessels (De Bock
et al, 2013; Cruys et al, 2016). In parallel, fatty acid oxidation,
which could also potentially sustain ATP production, supports the
synthesis of precursors in endothelial cells for nucleotide
biosynthesis (Schoors et al, 2015).
These findings highlight the possibility that targeting meta-
bolic pathways shared between cancer and stromal cells
could provide a multi-pronged approach for cancer therapy.
Nevertheless, they also illustrate that a deeper, systematic
analysis of immune cell metabolism in various tumours would
be required to evaluate the feasibility of this idea. For example,
significant efforts have been invested in inhibiting glucose
catabolism in tumours; however, limiting glucose uptake in
tumours, instead, may be preferable, because it would be
predicted to both undermine cancer metabolism, as well as
restore the function of tumour-infiltrating T cells and endothelial
cells. The latter could permit the maintenance of blood vessels
necessary for the delivery of therapeutic agents to the tumours.
Furthermore, although the above examples focus on T cells, given
the importance of specific metabolic pathways on the function of
almost every immune cell type studied to date, similar paradigms
are likely applicable for other immune cell types. Ultimately, it is
likely that the dynamics of nutrients in the tumour microenviron-
ment, in addition to cell-intrinsic metabolic dependencies of
immune cells may orchestrate the cellular profile of the stroma
within each tumour.
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Figure 3. Paradigms of cancer–immune cell interactions. (A) Tryptophan metabolism yields the intermediate kynurenine, which promotes
glioblastoma development by activating the aryl hydrocarbon receptor, a transcription factor that controls the expression of pro-tumorigenic
genes. A downstream product of further kynurenine catabolism is NAD, which, among others, is an essential co-factor for the DNA repair enzyme
poly-ADP ribose polymerase (PARP). Suppression of NAD synthesis by oncogenic signalling in liver tumours leads to increased genomic instability,
thereby promoting tumorigenesis. Th17 cell differentiation can be influenced by tryptophan metabolites and Th17-mediated inflammation has
been implicated in liver cancer. Whether tryptophan metabolism in cancer cells influences tumour progression by modulating immune cells
remains to be seen. (B) Metabolic competition for glucose between cancer cells and tumour-infiltrating T cells. In the proximity of highly glycolytic
cancer cells, T cells fail to sustain cytoplasmic calcium levels necessary to activate the NFAT transcription factor, which mediates anti-tumour
responses of T cells. The immunosuppressive molecule PD-L1 in cancer cells, may further promote glucose metabolism by signalling through the
mechanistic target of rapamycin (mTOR) pathway, in addition to suppressing T cells via interaction with PD-1. ER, endoplasmic reticulum; NFAT,
nuclear factor of activated T cells; PD-1, programmed cell death protein 1; PD-L1, PD ligand 1; PEP; phosphoenolpyruvate; SERCA, sarcoplasmic/
endoplasmic reticulum calcium ATPase; TCR, T-cell receptor; TDO, tryptophan dioxygenase.
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SUMMARY AND PERSPECTIVES
The microenvironments of various tumours are heterogeneous,
partly because they integrate the varying metabolic behaviours of
multiple cell types. Constant recruitment and turnover of these
cells in conjunction with distinct cancer cell metabolic needs
influence the dynamics of tumour metabolism through the various
stages of cancer development. As a result, although, clearly, some
of the metabolic characteristics of cancer cells are determined by
the underlying genetic background, it is hard to conceive a single
metabolic profile even for one type of cancer in the context of a
constantly evolving metabolic landscape within the tumour
microenvironment.
Studies of cancer metabolism in living higher organisms are
uncovering the influence of metabolic interactions with the
proximal environment. In addition, these experimental systems
can reveal the influence of distal factors, such as nutrient
metabolism via organs other than where the tumour is growing,
or the resident microflora, the role of which in tumorigenesis is
indicated by epidemiological evidence. At the same time, although
yielding a physiological picture of tumour metabolism, these
factors further convolute the process of pinpointing the source of
specific metabolic phenotypes (Pichumani et al, 2016), and this
may complicate the design of strategies for targeted therapeutics.
The development of imaging methods to study metabolism at
the single-cell level in autochthonous settings will be invaluable in
overcoming such limitations. In parallel, as we better understand
the microenvironmental factors that influence the metabolic
behaviours of cancer cells in physiological settings, there is a
persistent incentive to successfully translate this knowledge into
meaningful cell culture conditions. The advantages of using
primary tumour cells isolated from mouse models or patients
can be further broadened by mimicking tumour microenvironment
factors, such as oxygen, nutrient and extracellular matrix
conditions, which, in some settings, allow the recapitulation of
in vivo metabolic behaviours also in vitro (Bensaad et al, 2014;
Tardito et al, 2015). Furthermore, screening, testing and validation
of new therapeutics can be tremendously expedited and scaled up
in cultured cells.
Finally, appreciating the metabolic needs of both epithelial and
stromal cells not only in fully-formed, proliferative tumours, but
throughout tumour development may expand the scope of
targeting metabolism for therapeutic purposes also for cancer
prevention.
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